Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427110 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNATDP1HPGD | |
| SCHEMBL8566301 | 0.83 | MEN1 (0.62) | ALDH1A1TSHRTDP1HPGDMEN1 | |
| SCHEMBL2558483 | 0.81 | ALDH1A3 (0.58) | ALDH1A1LMNATDP1MEN1KMT2A | |
| SCHEMBL9856346 | 0.81 | SMN1; SMN2 (0.49) | ALDH1A1LMNATDP1MEN1KMT2A | |
| SCHEMBL11850072 | 0.80 | LMNA (0.52) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL20787503 | 0.80 | GAA (0.53) | ALDH1A1LMNATDP1MEN1KMT2A | |
| SCHEMBL14228482 | 0.79 | KMT2A (0.52) | ALDH1A1TSHRLMNAHPGDMEN1 | |
| SCHEMBL1931468 | 0.79 | KMT2A (0.52) | ALDH1A1TSHRLMNAHPGDMEN1 | |
| SCHEMBL8431462 | 0.79 | KMT2A (0.52) | ALDH1A1TSHRLMNAHPGDMEN1 | |
| SCHEMBL10175698 | 0.79 | KDM4E (0.67) | ALDH1A1LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | ALDH1A1 472/4885TSHR 1029/4885LMNA 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.